FDA • REMS • Pharmacy Operations • Isotretinoin

iPLEDGE Changes Isotretinoin Authorization and Pickup Rules

The iPLEDGE program lists November 15 as the effective date for revised isotretinoin requirements. Under its updated instructions, pharmacists enter the prescriber’s National Provider Identifier to obtain authorization for patients who cannot get pregnant. The program no longer assigns a dispense-by date for that group. The seven-day pickup window continues for patients who can get pregnant. A patient who misses the first window needs a repeat pregnancy test in a medical setting before starting treatment, and the additional waiting period has ended.

By Toby C. “Chad” Frost • November 16, 2026
1 min read

What the program changed

FDA approved changes to the isotretinoin safety program in February and moved the planned implementation date to November 15. The iPLEDGE program now lists the revisions as effective on that date.12

To get authorization for patients who cannot get pregnant, the pharmacist enters the prescriber’s National Provider Identifier. The program no longer assigns a dispense-by date for those patients. Pharmacies must reverse the authorization in iPLEDGE if the prescription returns to stock. Each fill still requires a new prescription and authorization, a Medication Guide, and a supply of no more than 30 days. The pharmacy’s authorized representative must document training at enrollment and annually thereafter.13

The seven-day pickup window continues for patients who can get pregnant. If a patient misses that window before starting treatment, they can repeat the required confirmatory pregnancy test in a medical setting without the previous waiting period.123

Checking the pharmacy workflow

Chad’s analysis. Build the prescriber identifier check into the authorization workflow. Keep patient category visible during pickup review so staff can distinguish a seven-day pickup window from a 30-day supply limit. Put the authorization reversal in the same checklist staff use to return the unused prescription to stock.

Source notes

  1. U.S. Food & Drug Admin., iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) (Feb. 9 & June 16, 2026 updates).
  2. iPLEDGE REMS, Program Changes (effective Nov. 15, 2026).
  3. iPLEDGE REMS, Pharmacist Guide 5–9 (Oct. 7, 2026).